INS and cancer: Several mechanisms through which metformin could have anti-cancer properties have been proposed, most of which involve AMP kinase activation that leads to inhibition of the insulin/IGF-1 pathway, mammalian target of rapamycin (mTOR) pathway, and human epidermal growth factor receptor type 2 (HER-2) expression [29–31].